RecruitingNCT05326399

Renal Biopsies in Post-liver Transplantation Patients With Renal Impairment

Renal Biopsies in Post-liver Transplantation Patients With Renal Impairment: a Single-center, Prospective Cohort Study

Sponsor

RenJi Hospital

Enrollment

369 participants

Start Date

Jun 1, 2022

Study Type

OBSERVATIONAL

Conditions

Liver Transplantation Renal Insufficiency, Chronic

Summary

Investigators will conduct this single-center, prospective cohort study to explore the prevalence and risk factors of renal function progression in post-liver transplantation patients with renal impairment after renal biospy and to understand the the pathology of kidney disease in post-liver transplantation patients with renal impairment.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study performs kidney biopsies in liver transplant patients who develop kidney problems after the transplant, to better understand what is causing the damage and guide treatment decisions. **You may be eligible if...** - You have received a liver transplant - You are experiencing worsening kidney function after your transplant - You are 18 or older - Your kidney function decline meets the criteria that warrant a biopsy **You may NOT be eligible if...** - You have a bleeding disorder or clotting abnormality making biopsy unsafe - You are on blood thinners that cannot be stopped - You have a single kidney or kidney abnormality making biopsy too risky Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALrenal biospy

Standard percutaneous biopsy has been performed in all participants. Modification of treatment will be jointly decided by hepatologists and nephrologists based on the pathological results. All participants will be followed up for 96 weeks.